DC Chemicals Limited
China
Product Name: CNQX disodium salt
Price: $350.0/100mg $550.0/250mg $1100.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

479347-85-8

479347-85-8 structure

Name: CNQX disodium
Chemical Name: CNQX disodium salt
CAS Number: 479347-85-8
Molecular Formula: C₉H₂N₄Na₂O₄
Molecular Weight: 276.116
Catalog: Signaling Pathways Membrane Transporter/Ion Channel iGluR
Create Date: 2018-05-20 08:00:00
Modify Date: 2024-01-13 13:15:01
CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist[1]. CNQX disodium blocks the expression of fear-potentiated startle in rats[5].

Name	CNQX disodium salt
Synonyms	Disodium 6-cyano-7-nitro-2,3-quinoxalinediolate disodium 6-cyano-7-nitroquinoxaline-2,3-diolate 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-, sodium salt (1:2)

Description	CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist[1]. CNQX disodium blocks the expression of fear-potentiated startle in rats[5].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> iGluR Research Areas >> Neurological Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> iGluR
Target	IC50: 0.3 μM (AMPA) and 1.5 μM (kainate receptor)[1]
In Vitro	CNQX disodium (FG9065 disodium; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices[2]. CNQX disodium (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments[3].
In Vivo	CNQX disodium (FG9065 disodium; 0.75-3 mg/kg; IP; 20 min before testing) decreased the number of cocaine responses in a dose-dependent manner during the first 15-min cocaine-free interval[4]. The bilateral infusion of CNQX disodium (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX disodium causes a complete blockade at a dose of 0.5 μg[5]. Animal Model: Male Wistar rats weighing 180-200 g[4] Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval.
References	[1]. T Honoré, et al. Quinoxalinediones: Potent Competitive non-NMDA Glutamate Receptor Antagonists. Science. 1988 Aug 5;241(4866):701-3. [2]. Neuman RS, et al. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione(CNQX) in the hippocampus in vitro. Neurosci Lett. 1988 Sep 23;92(1):64-8. [3]. Alford S, et al. CNQX and DNQX block non-NMDA synaptic transmission but not NMDA-evoked locomotion in lamprey spinal cord. Brain Res. 1990 Jan 8;506(2):297-302. [4]. Pia Bäckström, et al. Attenuation of Cocaine-Seeking Behaviour by the AMPA/kainate Receptor Antagonist CNQX in Rats. Psychopharmacology (Berl). 2003 Feb;166(1):69-76. [5]. Kim M, et al. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993 Jan;59(1):5-8.

Molecular Formula	C₉H₂N₄Na₂O₄
Molecular Weight	276.116
Exact Mass	275.987152

479347-85-8	115066-14-3
135326-22-6	81012-87-5
12055-09-3	5550-12-9
515-76-4	24704-41-4
51963-61-2	12267-73-1